Advertisement

Advertisement
Lymphoma

B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab

As reported in the Journal of Clinical Oncology by L. Elizabeth Budde, MD, PhD, and colleagues, extended follow-up of the dose-escalation phase of a phase I/II trial...

Lung Cancer

Lung Cancer Screening Eligibility: Effect of Using History vs Pack-Year History of Smoking

In a study reported in the Journal of Clinical Oncology, Potter et al found that use of a smoking history of ≥ 20 years rather than the current 2021...

Issues in Oncology
Bladder Cancer

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer...


Advertisement
Issues in Oncology
Prostate Cancer

Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients

Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings...

Solid Tumors
Hematologic Malignancies
Issues in Oncology

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers...

Advertisement
Advertisement




Sponsored Content


Breast Cancer
Immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Bladder Cancer
Immunotherapy

KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma

As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Leukemia
Immunotherapy

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Lung Cancer
Genomics/Genetics

Global Registry Analysis of NRG1 Fusion–Positive Lung Cancer

In an analysis from the global eNRGy1 registry for NRG1 fusion–positive lung cancers reported in the Journal of Clinical Oncology, Alexander Drilon, MD, and colleagues found greater than expected heterogeneity in characteristics of disease. Additionally, patients had poor responses to cytotoxic,...

Gynecologic Cancers
Cost of Care

Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity

In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lymphoma

Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection

The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter